In MCL, ibrutinib-resistant tumors exhibit aberrant ROR1 expression, which interacts with CD19 to form a functional signaling complex, promoting cell survival independent of the BCR–BTK axis (35). Here, CD19 is linked to mantle cell lymphoma.